Imlunestrant(Imlunestrant) - 药物靶点：ER_在研适应症：ER阳性/HER2阴性乳腺癌，肝损伤，晚期乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Imlunestrant Tosylate、LY-3484356

靶点

ER

作用机制

ERs降解剂(雌激素受体家族降解剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病消化系统疾病+ [1]

在研适应症

ER阳性/HER2阴性乳腺癌肝损伤晚期乳腺癌+ [4]

非在研适应症-

原研机构

Eli Lilly & Co.

在研机构

Eli Lilly & Co.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C29H24F4N2O3

InChIKeyUVBQMXOKKDCBJN-MUUNZHRXSA-N

CAS号2408840-26-4

关联

16

项与 Imlunestrant 相关的临床试验

CTR20231037

/ Terminated临床1期

一项LOXO-783单药治疗和与其他抗癌疗法联合治疗PIK3CA H1047R突变的晚期乳腺癌和其他实体瘤患者的研究

主要目的：确定在PIK3CA H1047R突变的晚期乳腺癌和其他实体瘤患者中 LOXO-783单药治疗和与其他抗癌疗法联合治疗的LOXO-783的MTD/RP2D

开始日期2023-11-27

申办/合作机构

礼来苏州制药有限公司

[+2]

CTR20230192

/ Recruiting临床3期

EMBER-4：一项在既往接受过2-5年辅助内分泌治疗的ER+、HER2-早期乳腺癌且具有较高复发风险的患者中比较Imlunestrant辅助治疗和标准辅助内分泌治疗的随机、开放性、III期研究

本研究的主要目的是在雌激素受体阳性（ER+）和人表皮生长因子受体2阴性（HER2-）早期乳腺癌受试者中评价Imlunestrant相比标准内分泌治疗的疗效。入组研究的受试者必须符合以下条件：既往接受过2-5年的内分泌治疗、具有较高的复发风险。受试者参与研究的持续时间可能长达10年。

开始日期2023-05-12

申办/合作机构

礼来苏州制药有限公司

[+2]

CTIS2022-501007-28-00

/ Recruiting临床3期

J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence - 18459

开始日期2023-04-27

申办/合作机构

Eli Lilly & Co.

100 项与 Imlunestrant 相关的临床结果

登录后查看更多信息

100 项与 Imlunestrant 相关的转化医学

登录后查看更多信息

100 项与 Imlunestrant 相关的专利（医药）

登录后查看更多信息

11

项与 Imlunestrant 相关的文献（医药）

2025-03-01·Nature Reviews Clinical Oncology

Imlunestrant shows efficacy both with and without abemaciclib

Article

作者: Killock, David

2025-02-17·CANCER RESEARCH

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Article

作者: Shen, Weihua ; Kindler, Lisa ; de Dios, Alfonso ; Garcia-Tapia, David ; Dowless, Michele S. ; Ortiz Ruiz, Maria Jesus ; Bastian, Jolie ; Rodrik-Outmezguine, Vanessa ; Rodriguez Cruz, Vivian ; Yu, Chunping ; Castanares, Mark A. ; Klippel, Anke ; Bhagwat, Shripad V. ; Marugán, Carlos ; Mattioni, Brian ; Fei, Dongling ; Vandekopple, Matthew ; Cohen, Jeff D. ; Ismail-Khan, Roohi ; Gong, Xueqian ; Stephens, Jennifer R. ; Peng, Sheng-Bin ; Capen, Andrew ; Bacchion, Francesca ; Puca, Loredana ; Zhao, Baohui ; Lallena, María Jose ; Yuen, Eunice ; Manro, Jason R. ; Baker, Thomas K. ; Pulliam, Nicholas ; Mur, Cecilia ; Huber, Lysiane

Abstract:

Targeting of the estrogen receptor (ER) by antiestrogens is the standard of care for patients with ER+ HER2− advanced/metastatic breast cancer. Although antiestrogens that degrade ERα (fulvestrant) or block estrogen production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack of brain exposure, and acquired resistance due to ESR1 mutations. These limitations indicate a need for more robust ER-targeted therapies. Here, we discovered and characterized imlunestrant, a next-generation potent, brain-penetrant oral selective ER degrader. Imlunestrant degraded ERα and decreased ERα-mediated gene expression both in vitro and in vivo. Cell proliferation and tumor growth in ESR1 wild-type (WT) and mutant models were significantly inhibited by imlunestrant. Combining imlunestrant with abemaciclib (CDK4/6 inhibitor), alpelisib (PI3K inhibitor), or everolimus (mTOR inhibitor) further enhanced tumor growth inhibition, regardless of ESR1 mutational status. In an ER+ breast cancer intracranial tumor model, imlunestrant prolonged survival compared with vehicle or alternative selective ER degrader therapies. Together, these findings support the potential of imlunestrant to degrade ERα and suppress the growth of ESR1-WT and mutant breast cancer, including brain metastatic tumors.Significance: Imlunestrant, a next-generation, brain-penetrant oral ERα degrader, displays potent activity in ESR1 wild-type and mutant breast cancer, enhances combination activity with standard-of-care agents, and inhibits growth of ER+ intracranial tumors.

2025-01-27·Annual Review of Medicine

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer

Review

作者: Pathak, Neha ; Oliveira, Mafalda

Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor–positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials—elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant—with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies. This review summarizes the currently available literature on this new class of drugs.

50

项与 Imlunestrant 相关的新闻（医药）

2025-02-26

·Endpoints

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

AstraZeneca wasn’t expected to have data from the Phase 3 trial of its oral SERD until the second half of this year so the positive interim results that the UK drugmaker detailed on Wednesday may be a step toward its blockbuster ambitions for the drug. The SERENA-6 study is one of several late-stage investigations of camizestrant. It tested the pill in what AstraZeneca calls a first-line setting. However, the trial had a switching design, and further data will likely be necessary before the experimental medicine is accepted for first-line use by regulators and prescribers. The trial combined camizestrant with a CDK4/6 inhibition in ER-positive, HER2-negative breast cancer, and AstraZeneca said it resulted in a “highly statistically significant and clinically meaningful” benefit on the primary endpoint of progression-free survival over standard therapy. The participants started the trial being treated with an aromatase inhibitor on top of a CDK4/6 inhibitor — either Pfizer’s Ibrance, Novartis’ Kisqali or Eli Lilly’s Verzenio. The aromatase inhibitor/CDK inhibitor approach is standard first-line care for ER-positive breast cancer, but around 30% of patients can develop a mutation in the ESR1 gene as a mechanism of resistance to these drugs. ESR1 encodes one of the two main types of estrogen receptor. Patients with ESR1 mutations are the only population in whom SERDs — or selective estrogen receptor degraders — have so far been shown to work. A recent example is Lilly’s imlunestrant, which was revealed in December to show a second-line benefit in mutants, but not those with wild-type ESR1 genes. Patients in AstraZeneca’s SERENA-6 trial were monitored for these mutations with blood tests. If an ESR1 mutation was found before the patient’s disease had progressed, they were switched from the aromatase inhibitor regimen to camizestrant plus one of the CDKs. These patients had better PFS than those who stayed on the initial regimen. Arguably this is not strictly a first-line population since patients had already received aromatase and CDK4/6 blockade. AstraZeneca said data on secondary endpoints, including overall survival and time to second disease progression (PFS2), are not yet mature, though it noted that there was a trend toward improvement in PFS2 with the camizestrant combo. No new safety concerns were seen, according to AstraZeneca, and dropouts were “very low and similar in both arms.” AstraZeneca has suggested camizestrant’s sales could peak at more than $5 billion, Barclays analysts wrote in a Wednesday note. But the analysts themselves forecast peak sales of $3.6 billion, evenly split between the first-line and adjuvant settings. Reaching this goal will likely be dependent on an overall survival benefit emerging from SERENA-6, as well as success in the other three ongoing late-stage trials of the SERD. Data from the CAMBRIA-1 and -2 trials in the adjuvant setting could come later this year or early next year. Perhaps more importantly, the SERENA-4 study is in a clearer first-line setting, having enrolled patients who have not previously received systemic treatment. Those patients will get either camizestrant plus Ibrance or an aromatase inhibitor plus Ibrance. Data are expected in 2026 and could help settle the question of whether camizestrant could have a future as first-line therapy.

临床3期临床结果

2025-02-26

·FierceBiotech

AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD

AstraZeneca plans to share interim phase 3 data on camizestrant with global regulatory authorities.\n AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its primary endpoint, but is yet to show patients live longer on the drug candidate.Racing rivals including Eli Lilly and Roche, AstraZeneca is striving to establish the endocrine therapy as a backbone drug in hormone receptor-positive, HER2-negative breast cancer. AstraZeneca’s rivals have similar ambitions, with multiple companies claiming their molecules could be best in class, and the field is now nearing the publication of the hard evidence that will help settle the debate.AstraZeneca landed an early blow Wednesday. At a planned interim phase 3 analysis, the drugmaker found PFS improved when breast cancer patients switched from a standard-of-care aromatase inhibitor to camizestrant.The study has a novel design that reflects an unmet need in the indication. All patients received an aromatase inhibitor and a CDK4/6 inhibitor—either Lilly’s Verzenio, Novartis’ Kisqali or Pfizer’s Ibrance—as their first-line treatment. Physicians monitored circulating tumour DNA to spot ESR1 mutations. If a mutation was found before disease progression, patients switched to camizestrant and stayed on the CDK4/6 drug. ESR1 mutations are found in about 5% of patients at the time of metastatic diagnosis, Susan Galbraith, Ph.D., executive vice president of oncology R&D at AstraZeneca, said on an earnings call this month. The figure rises to around 40% by the time of disease progression at the end of first-line treatment. AstraZeneca designed the trial to show whether camizestrant can extend the benefit of first-line therapy for those patients.The primary endpoint hit suggests that goal is within reach, but questions remain. The data on time to second disease progression (PFS2) and overall survival (OS) were immature at the time of the interim analysis. AstraZeneca noted a trend toward improvement in PFS2 but made no further comment on its OS data. No new safety concerns were seen, and discontinuations were very low, AstraZeneca said.The PFS endpoint is the first of a series of milestones for the program. AstraZeneca is running another trial in a broader first-line population and two adjuvant studies. Through the program, the company is aiming to establish camizestrant as a new backbone therapy and hit a peak sales target that AstraZeneca CEO Pascal Soriot has set at more than $5 billion.AstraZeneca could face competition. Lilly reported phase 3 data on its oral SERD imlunestrant in patients who progressed on an aromatase inhibitor late last year. Roche is aiming to have data on giredestrant, its challenger for the market, sometime from mid-2025 onward. AstraZeneca sees the safety profile of its candidate and ability to combine it with a range of other drugs as differentiators. “The safety profile that we\'re seeing with camizestrant leads to an extremely low discontinuation rate, very low rates of these GI side effects, which I think is important, particularly when you go into the earlier lines of therapy. People want to stay on the drug for a long period of time,” Galbraith said. “I think the overall profile that we have with this drug is really looking best in class from our perspective.”AstraZeneca plans to share the interim phase 3 data with global regulatory authorities.

临床3期临床结果

2025-02-25

·药时空

超1200亿美元！2024年全球制药巨头研发投入TOP10

在全球医药行业的激烈竞争中，研发投入是各大制药巨头保持竞争力的关键。2024 年，这些企业在研发上的投入情况备受关注，这不仅体现了它们的创新实力，还预示着行业未来的发展方向。下面就来看看2024年研发投入位居前十的制药巨头都有哪些。 2024 年制药巨头研发投入 TOP10 分别是默沙东、强生、罗氏、阿斯利康、艾伯维、百时美施贵宝（BMS）、礼来、辉瑞、诺华和赛诺菲。这十家企业的总投入超过 1200 亿美元，展现出对创新研发的高度重视。表1：2024年制药巨头研发投入TOP10 默沙东以 179.38 亿美元的研发投入蝉联榜首。不过，相较于 2023 年的 305.31 亿美元，其投入大幅下降了 41.25%。这主要是因为 2023 年默沙东进行了几笔大额交易，拉高了当年的研发投入。作为默沙东的王牌产品，Keytruda（帕博利珠单抗，简称 K 药）2024 年销售额达到 294.82 亿美元，约占公司全年总营收的 46% 。为了应对 2028 年 K 药专利到期的情况，默沙东积极拓展其早期适应症，开展联合用药布局，并开发皮下制剂。2024 年，K 药皮下制剂 3 期研究成功，给药时间大幅缩短。在 HPV 疫苗方面，Gardasil/Gardasil 9 在 2024 年销售额为 85.83 亿美元，2025 年 1 月，该疫苗在中国获批适用于 9 - 26 岁男性接种，进一步拓展了市场。此外，默沙东在心血管代谢、抗感染和眼科等领域也有不少在研项目，如心血管代谢领域的 Winrevair 等药物在临床试验中取得积极成果。强生 2024 年研发投入为 172.32 亿美元，较 2023 年增长 14.41%。其创新制药业务聚焦肿瘤、神经科学、感染性疾病等多个领域，肿瘤和自免领域对业绩贡献突出，合计贡献超 380 亿美元收入。在肿瘤领域，强生公布了 EGFR/c-MET 双抗 Rybrevant 联合第三代 EGFR 抑制剂 Lazertinib 的多项研究成果，联合疗法在治疗相关癌症方面表现出色，显著提高了患者的无进展生存期。罗氏 2024 年研发投入为 148.52 亿美元，与 2023 年相比变化不大。肿瘤学依旧是罗氏研发的重点领域，同时在免疫学和心血管、肾脏和代谢领域也投入颇多。2024 年，罗氏有多款产品取得后期临床积极进展，比如 Itovebi 在 III 期研究中显著延长了 PIK3CA 突变型 HR+/HER2 - 乳腺癌患者的无进展生存期，有望填补罗氏在乳腺癌领域因 Herceptin 专利到期后的收入缺口；PiaSky 作为补体药物，通过皮下给药方式挑战同类产品市场地位，并于 2024 年在美国和欧盟获批。不过，罗氏也削减了包括 TIGIT 抗体 tiragolumab 相关的多个临床项目，未来将重新评估资源分配。阿斯利康 2024 年研发投入为 135.83 亿美元，同比增长 24.19%。这一增长主要源于肿瘤学、心血管、肾脏及代谢、呼吸与免疫和罕见病领域的临床试验推进、新药上市准备以及对外技术平台投资。2024 年，阿斯利康完成了 9 项高商业潜力的 III 期临床试验，像 Tagrisso 针对 III 期不可切除非小细胞肺癌的研究取得成功，Enhertu 尝试进入未经化疗的转移性乳腺癌患者治疗场景等。2025 年，阿斯利康还将迎来多项监管和 III 期研究数据披露的重要节点，致力于巩固其在多个领域的领导地位。艾伯维 2024 年研发投入达 127.91 亿美元，同比增长 66.66%，凭借这一涨幅挤入前五。由于 Humira（阿达木单抗）专利到期，受到生物类似药竞争冲击，其销售额自 2022 年起持续下降，2024 年降至 89.93 亿美元。不过，艾伯维在自免领域推出的两款新药 IL-23 抑制剂 Skyrizi 和 JAK 抑制剂 Rinvoq 表现亮眼，2024 年销售额分别增长 50.9% 和 51%。此外，艾伯维在 2024 年至 2025 年初开展了一系列重大交易活动，如与多家公司合作开发针对肿瘤学和免疫学的创新药物，不断丰富自身研发管线。百时美施贵宝（BMS）2024 年研发投入为 111.59 亿美元，同比增长 20%。BMS 以 Opdivo（纳武利尤单抗，简称 O 药）为核心，积极拓展其应用边界，并推出了 O 药的皮下制剂。2024 年，O 药在多个方面取得进展，如美国 FDA 批准了 Opdivo Qvantig 用于多种实体瘤的皮下注射治疗，O 药与 Yervoy 联合疗法在相关癌症治疗中也显示出良好效果。同时，BMS 的 CAR-T 细胞疗法 Breyanzi 针对复发或难治性大 B 细胞淋巴瘤展现出持久疗效，其适应症也在进一步扩展。另外，BMS 在心血管、自免和神经领域也有成果，如心血管领域 Camzyos 的标签更新，自免领域 Sotyktu 治疗活动性银屑病关节炎的研究达到主要终点等。2025 - 2027 年，BMS 还将密集迎来重磅临床数据读出，为公司业务发展带来新契机。礼来 2024 年研发投入为 109.91 亿美元，同比增长 18.02%。核心产品替尔泊肽不仅贡献了 164.66 亿美元的收入，还获批用于中重度阻塞性睡眠呼吸暂停合并肥胖症的治疗。在肿瘤领域，礼来的非共价 BTK 抑制剂和 Imlunestrant 等药物在相关研究中取得积极结果。此外，礼来在 2024 年积极开展 BD 交易，围绕多个医学领域达成十余项重磅合作，交易总金额超 50 亿美元，加速了创新药物的研发进程。辉瑞 2024 年研发投入为 108.22 亿美元，较 2023 年增长 1.34%。2023 年底收购 Seagen 后，辉瑞强化了 ADC 管线。2024 年，Seagen 的多个 ADC 项目取得突破，如 Adcetris 联合治疗方案获批成为新疗法，Enfortumab Vedotin 与 K 药联合疗法开展 III 期研究，Sigvotatug vedotin 针对 PD-L1 高表达非小细胞肺癌的临床研究进入 III 期等。同时，辉瑞的其他在研药物也有进展，如 BCMA-CD3 双抗 ELREXFIO™在多发性骨髓瘤研究中展现出生存获益。疫苗方面，RSV 疫苗 ABRYSVO® 获批用于 18 - 59 岁人群，扩大了适用范围。辉瑞计划通过 “成本重组计划” 节省资金，支持高优先级管线的研发。诺华 2024 年研发投入为 100.22 亿美元，同比下降 11.86%。诺华聚焦心 - 肾 - 代谢疾病、免疫学、神经科学、肿瘤学四大核心治疗领域以及基因与细胞治疗、放射性配体疗法、xRNA 三大新兴技术平台。在肿瘤学领域，治疗前列腺癌的 Pluvicto® 和慢性髓系白血病疗法 Scemblix® 都有积极进展；免疫学领域，Cosentyx（司库奇尤单抗）相关研究预计 2025 年公布数据；神经科学领域，与 PTC Therapeutics 合作开发的亨廷顿病口服疗法和脊髓性肌萎缩基因疗法都按计划推进；心 - 肾 - 代谢疾病领域，Fabhalta 在相关研究中显示出治疗效果，有望获批新适应症。2024 年，诺华还通过并购和合作，加强了自身研发能力。赛诺菲 2024 年营收 410.81 亿欧元（约 445.61 亿美元，按 2024 年平均汇率 1 欧元 = 1.0847 美元换算，下同）；研发投入 73.94 亿欧元（约 80.20 亿美元），同比增长 14.6%。免疫王牌产品度普利尤单抗陆续在欧美中三地获批慢阻肺病适应症，2024 年全球销售额达到 141.79 亿美元。在成功跨越慢阻肺病后，度普利尤单抗将目光聚焦于新的战场 —— 慢性自发性荨麻疹以及大疱性类天疱疮领域，开启了新一轮的攻坚冲刺。在自免领域，赛诺菲的研发 “弹药库” 远不止度普利尤单抗这一 “明星单品”，其管线储备极为丰富，诸如 IL-33 单抗 Itepekimab、单抗 Amlitelimab（OX40L）、口服 BTK 抑制剂 Rilzabrutinib 等多款药物。在罕见病领域，赛诺菲推出 12 款产品。 2024 年全球制药巨头研发投入 TOP10 榜单展示了这些企业在创新研发上的决心和战略布局。它们的研发投入策略反映了医药行业的发展趋势，从对核心产品的持续挖掘，到新兴技术和领域的探索，都为全球医药行业的进步注入了强大动力。期待这些企业未来能凭借研发成果，为患者带来更多有效的治疗方案，推动全球医药行业迈向新高度。参考资料：[1]2024年MNC研发投入TOP10.药智网.2025年02月24日.[2]2024年全球制药巨头研发投入TOP10.医药魔方.2025年02月24日. 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床3期专利到期疫苗

100 项与 Imlunestrant 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
ER阳性/HER2阴性乳腺癌	临床3期	美国	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	中国	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	日本	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	阿根廷	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	澳大利亚	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	奥地利	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	比利时	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	巴西	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	捷克	Eli Lilly & Co.	2021-10-04
ER阳性/HER2阴性乳腺癌	临床3期	法国	Eli Lilly & Co.	2021-10-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04975308 (EMBER-3, Pubmed \| SABCS2024) 人工标引	临床3期	晚期乳腺癌	874	Imlunestrant	簾製簾範鹹鏇憲選艱壓(繭鬱範窪願糧襯餘醖齋) = 製憲淵遞醖願鏇鹹鏇艱繭鹽醖鏇構鑰鑰鹹襯觸 (製糧壓願網築蓋壓醖艱 ) 更多	积极	2024-12-11
				Standard therapy	簾製簾範鹹鏇憲選艱壓(繭鬱範窪願糧襯餘醖齋) = 繭鹽鬱齋齋構蓋鬱鏇膚繭鹽醖鏇構鑰鑰鹹襯觸 (製糧壓願網築蓋壓醖艱 ) 更多
NCT04188548 (EMBER, Pubmed \| J Clin Oncol) 人工标引	临床1期	ER阳性/HER2阴性乳腺癌 HER2 Negative \| Estrogen receptor	262	Imlunestrant monotherapy	窪鏇淵鑰網衊構憲構鏇(網鏇顧願壓積構簾鬱選) = 獵觸襯製選積觸窪製憲廠淵積鑰襯餘築鹽鏇積 (艱願顧襯齋憲範窪膚遞 ) 更多	积极	2024-09-06
				Imlunestrant + abemaciclib	艱簾衊觸膚選糧觸糧製(簾範獵鑰獵壓鏇襯遞廠) = 鹹遞獵鬱淵顧選築襯獵鑰範醖鹹獵顧築網鏇艱 (襯繭夢醖網淵艱壓選齋, 13.8 ~ NA)
NCT04188548 (EMBER, ASCO2024) 人工标引	临床1期	子宫内膜癌 ER+	72	Imlunestrant 400mg po daily	膚願鏇糧襯齋憲鹽壓選(壓獵窪憲衊願壓夢簾鏇) = 蓋夢襯艱鑰餘範製窪積齋壓淵蓋簾膚製鹹積獵 (糧顧糧廠壓艱簾憲膚遞 ) 更多	积极	2024-05-24
				Imlunestrant 400mg po daily + Abemaciclib 150mg po twice daily	膚願鏇糧襯齋憲鹽壓選(壓獵窪憲衊願壓夢簾鏇) = 鹹膚鏇繭糧衊艱觸獵餘齋壓淵蓋簾膚製鹹積獵 (糧顧糧廠壓艱簾憲膚遞 ) 更多
NCT04188548 (EMBER, ASCO2024) 人工标引	临床1期	ER阳性/HER2阳性乳腺癌 HER2 Positive	45	Imlunestrant + Trastuzumab	蓋鬱繭觸蓋鹽餘觸膚醖(蓋襯選繭鬱夢淵鏇窪製) = 願願範積鬱遞衊壓艱鏇觸鬱齋選鬱積窪鏇鏇積 (築選獵鑰蓋鹹夢網糧壓 ) 更多	积极	2024-05-24
				Imlunestrant + Trastuzumab + Abemaciclib	蓋鬱繭觸蓋鹽餘觸膚醖(蓋襯選繭鬱夢淵鏇窪製) = 顧蓋窪鹹餘醖膚憲襯繭觸鬱齋選鬱積窪鏇鏇積 (築選獵鑰蓋鹹夢網糧壓 ) 更多
NCT04188548 (EMBER, ESMO_BC2024) 人工标引	临床1期	ER阳性/HER2阴性乳腺癌 HER2 Negative \| ER Positive	109	Imlunestrant	鏇鏇醖鑰衊窪觸鬱願鹽(艱窪觸觸鹹築鏇鹹選糧) = 糧鑰構選壓範願繭範鹽築顧築醖製選鑰鑰繭觸 (壓遞繭膚築憲夢選築艱, 32 ~ 52)	不佳	2024-05-14
				Imlunestrant (without baseline detectable ctDNA)	鏇鏇醖鑰衊窪觸鬱願鹽(艱窪觸觸鹹築鏇鹹選糧) = 鑰簾遞願衊蓋醖醖襯糧築顧築醖製選鑰鑰繭觸 (壓遞繭膚築憲夢選築艱 )
EMBER (Biospace) 人工标引	临床1期	ER阳性/HER2阴性乳腺癌末线 ER Positive \| HER2 Negative	-	Imlunestrant + Verzenio + AI	壓鏇鏇選範築選獵觸構(齋醖廠衊齋壓築壓積醖) = 構艱選網壓鑰膚築夢鹽觸積簾襯願淵觸壓醖鹹 (淵願壓顧製鹹淵積積襯 ) 更多	积极	2023-12-05
				Imlunestrant + Verzenio	壓鏇鏇選範築選獵觸構(齋醖廠衊齋壓築壓積醖) = 製齋衊簾繭糧憲範夢蓋觸積簾襯願淵觸壓醖鹹 (淵願壓顧製鹹淵積積襯 ) 更多
NCT04188548 (EMBER, ESMO 12023 \| ESMO 22023) 人工标引	临床1期	ER阳性/HER2阴性乳腺癌 HER2 Negative \| ER Positive	177	Imlunestrant	構鬱夢艱構鬱積糧構廠(蓋窪艱衊選獵壓糧獵築) = Imlunestrant monotherapy (Nausea 40%,Fatigue 32%,Diarrhea 31%);Imlunestrant + everolimus ( Diarrhea 55%,Fatigue 45%, AST increase 38%);Imlunestrant + alpelisib (Diarrhea 86%,Rash 67 %,Hyperglycaemia 62%) 簾築齋鬱遞獵遞觸窪積 (窪憲築網網壓鬱艱醖蓋 )	积极	2023-10-22
				Imlunestrant + everolimus
NCT04188548 (EMBER, ASCO2022)	临床1期	子宫内膜样腺癌 \| ER阳性乳腺癌	138	Imlunestrant	觸夢餘憲壓艱積顧鹹壓(餘壓觸憲鹹淵艱壓顧積) = 鏇廠蓋願鬱鏇築獵簾遞鹹鬱憲獵艱鬱製壓鑰廠 (築觸鬱鹽遞糧選窪廠積 ) 更多	-	2022-06-02
NCT04188548 (EMBER, ASCO 12021 \| ASCO 22021) 人工标引	临床1期	子宫内膜样腺癌 \| ER阳性乳腺癌 ER Positive	28	LY3484356	積獵鏇築繭膚蓋鑰範觸(廠獵選選窪築鹹遞選選) = 憲鬱齋淵憲鑰蓋衊膚壓鬱築範憲製繭餘築膚觸 (選構網積衊構築醖繭簾 ) 更多	积极	2021-05-20